Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

Description

The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty. The name of the screening blood test being studied is: -GRAIL Galleri MCED test

Conditions

Cancer Diagnosis

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty. The name of the screening blood test being studied is: -GRAIL Galleri MCED test

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

Condition
Cancer Diagnosis
Intervention / Treatment

-

Contacts and Locations

Boston

Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Active-duty or National Guard/Reserves military service for eight or more years
  • * Age ≥ 45
  • * Received care at a VA facility within past 5 years
  • * Able to sign informed consent
  • * Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if screening test indicates possible malignancy
  • * Individuals diagnosed with invasive malignancy within 3 years of enrollment (non- melanoma skin cancer is acceptable)
  • * Individuals with evidence of symptomatic or active cancer requiring therapeutic intervention at the time of participation (hormone therapy for breast/prostate cancer is acceptable)
  • * Individuals in the process of being evaluated for a clinical suspicion of cancer

Ages Eligible for Study

45 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Dana-Farber Cancer Institute,

Elizabeth ODonnell, MD, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

2028-09-30